Breast cancer developed in familial BRCA1 mutation carriers bears striking similarities to sporadic basal-like breast tumors. The mechanism underlying the function of BRCA1 in suppressing basal-like breast cancer remains unclear. We previously reported that the deletion of p18
INTRODUCTION
Mammary epithelia are mainly composed of luminal and basal or myoepithelial cells, both of which are believed to originate from a common stem cell. Accordingly, breast cancer can be divided into two major types: luminal-type and basal-like tumors. 1 Approximately 90% of breast cancers occur sporadically. The remaining 10% are inheritable, and half of these are linked with mutations in the BRCA1 gene. BRCA1 mutation carriers bear striking similarities to sporadic basal-like tumors. [2] [3] [4] [5] The mechanism underlying the function of BRCA1 in suppressing basal-like breast cancer remains unclear. A major hurdle in elucidating this issue has been the lack of suitable mouse models harboring a germline mutation of Brca1 and spontaneously developing basal-like mammary tumors.
Basal-like breast tumors developed in BRCA1 mutation carriers are thought to originate from either the mammary stem cell or basal progenitors. 6, 7 The predominant expression pattern of BRCA1 in mammary luminal epithelial cells in humans and mice, however, suggests that germline mutation of BRCA1 has a role in luminal cell development. Indeed, more recently a few groups observed that aberrant luminal progenitors might be the target for breast basal-like tumor development in BRCA mutation carriers, 8, 9 and knocking down of BRCA1 impaired luminal cell differentiation. 7, 10 Owing to the unknown genetic background of the patients and the limitation of the tissue sample collection, however, it remains elusive whether, and how, germline mutation of BRCA1 selectively targets luminal progenitors, leading to basallike tumor development and progression.
The functions of BRCA1 have been linked with multiple pathways, but have proven to be difficult to precisely define. Several biochemical functions have been described for the BRCA1 protein including transcriptional regulation, homologous recombination and ubiquitin ligase activity. 11, 12 At the cellular level, a theme has emerged that links the function of BRCA1 with genome integrity. A reduction of, or deficiency in, Brca1 function causes extensive chromosomal abnormalities, resulting in the activation of DNA-damage checkpoint pathways and inhibition of cell proliferation. [13] [14] [15] These findings suggest that overcoming growth inhibition resulting from the activation of cell cycle checkpoints may be a necessary step for the development of tumors initiated by Brca1 reduction or loss, as seen in Brca1 mutant mice combined with a mutation in p53 pathway. p18 Ink4c (referred to as p18 hereafter) is a member of the mammalian INK4 family that inhibits CDK4 and CDK6 whose activation by mitogen-induced D-type cyclins leads to phosphorylation and functional inactivation of RB, p107 and p130. Functional inactivation of this pathway, consisting of INK4-cyclin D/CDK4/6-Rb-E2F, is a common event in the development of most types of cancer. 16, 17 p18 is a haploinsufficient tumor suppressor in mice, 18 and deletion of p18 results in increased proliferation of stem or progenitor cells and development of pre-neoplastic or tumor phenotypes in multiple tissues or organs, including prostate, 19 neuroendocrine organs, 20 lung, 21 breast 22 and brain. 23 These studies established the concepts that an INK4 gene, p18, suppresses tumorigenesis by constraining stem or progenitor cells and that reduced RB pathway activity sensitizes cells to more rapid or malignant transformation when combined with heterozygosity of tumor suppressors from other pathways, including Pten, Men1 and p53. Mutation, or reduced expression, of the p18 gene has been observed in several types of human cancers including breast cancer. [24] [25] [26] [27] [28] spontaneously develop estrogen receptor (ER)-positive mammary luminal tumors at a high incidence. Deletion of p18 stimulates luminal progenitor cell proliferation at pubertal age and maintains an expanded luminal progenitor cell population throughout life. 22 Prompted by the predominant expression of Brca1 in luminal cells and growth defects caused by Brca1 deficiency and reduction, as well as the unique phenotype shown in p18-deficient mice-increased luminal progenitor cell proliferation and luminal tumor development-we hypothesized that loss of p18 may overcome Brca1-deficiency-induced growth inhibition, allowing us to determine the effect of germline mutation of Brca1 on mammary gland and tumor development. We generated p18;Brca1 double-mutant mice and discovered the function of Brca1 in maintaining luminal cell fate by preventing luminal progenitor cells from aberrant differentiation and suppressing the differentiation of basal/myoepithelial cell lineage. Germline mutation of Brca1 alters luminal epithelial cell fate and, when combined with the reduced function of the RB pathway, for example, p18 loss, induces luminal-to-basal transformation leading to basal-like tumor formation.
RESULTS

Deletion of p18 alleviates proliferative and developmental defects caused by heterozygous germline mutation of Brca1
To study the function of Brca1 in mammary gland, we first examined the expression of Brca1 in different epithelial cells. Fluorescence-activated cell sorting (FACS) sorted luminal progenitor-enriched CD24 þ CD29 À cells from wild-type mice at a pubertal age expressed 6.7-fold more Brca1 than CD24 À CD29 À cells that include basal/myoepithelial cells, stromal and other cells (Figure 1a ), indicating that Brca1 is predominantly expressed in the luminal epithelium. p18 mRNA level was inversely correlated with that of Brca1, and was significantly lower in luminal progenitor-enriched cells. Immunostaining of pubertal mammary glands further confirmed predominant Brca1 expression in the luminal epithelium (Figure 1b ). Haploid loss of Brca1 in primary mammary epithelial cells (MECs, Figure 1c ) increased p18 mRNA level, and knockdown of Brca1 in 293 T, T47D and MCF7 cells (Figure 1d ) led to a 1.3-to 1.5-fold increase in p18 mRNA and protein levels, suggesting that Brca1 negatively regulates p18. Brca1 À / À mice die embryonically and Brca1 þ / À causes various growth defects in tissues and animals, 13, 29, 30 preventing researchers from determining the effects of germline mutation of Brca1 in mammary gland and tumor development. Prompted by the observation of expanded luminal progenitor cells and mammary tumor development in p18-deficient mice and the inverse correlation between p18 and Brca1, we determined the genetic interaction between these two genes. We mated p18 -/-homozygotes with Brca1 þ /-heterozygotes to generate animals heterozygous for both genes. These mice were then intercrossed to generate both p18 À / À ;Brca1 þ /-and p18 þ / ;Brca1 þ / À animals. Genotype analysis of more than 600 offspring did not identify any p18 À / À ; Brca -/-double null mice, nor were any viable p18 À / À ; Brca À / À embryos identified beyond embryonic day 14.5 (data not shown). These results indicate that deletion of p18 does not rescue the embryonic lethality caused by Brca1 loss. Haploid loss of Brca1 caused by heterozygous germline mutation of Brca1, as expected, decreased mouse body weight from 12 to 24 weeks of age (Figure 1e ), inhibited cellular proliferation in young and old MECs (Ki67-positive cells, 10.2% in wild type and 3.3% in Brca1 þ /-for young, 3.6% in wild type and 0.8% in Brca1 þ /-for old MECs, respectively) (Figures 1f and g ), and induced premature senescence (Figures 1g-i) . Notably, p18 deficiency rescued body weight decrease and premature senescence (Figures 1e and h ) caused by heterozygous germline mutation of Brca1. The proliferation in 30-50% Brca1 þ / À mammary glands of each mouse was rescued by p18 loss at 2 months of age (Ki67-positive cells, 3.3% in Brca1 þ /-to 21% in p18 À / À ;Brca1 þ / À glands), although the proliferation of the remaining Brca1 þ / À glands (50-70%) was not rescued by p18 deficiency (Figure 1f ). When aging mice were examined, 3.6% Ki67-positive MECs were detected in wild-type females at 20 months of age, but only 0.83% Ki67-positive MECs were found in Brca1 þ / À littermates ( Figure 1g ). Loss of p18 rescued the proliferation of most mammary glands and led to tumor development in Brca1 þ / À background at this age (Figures 1g-i and data not shown). As it has been shown that overexpression of Brca1 causes cell cycle arrest by transactivating p21 in vitro 31, 32 and that Brca1 deficiency results in the increase of p21 and premature senescence in vivo, 13, 30, 33 we determined the expression of p21 and p16 INK4a , another INK4 member of cell cycle inhibitor, in these mutant mice. We found that p21 mRNA level was not altered in Brca1 þ / À mammary glands at 3 months of age, but increased by 2.9-and 3.1-fold in p18 À / À and p18 À / À ;Brca1 þ /-glands, respectively (Supplementary Figure S1) . p16
INK4a mRNA level was increased 1.7-fold in Brca1 þ / À , and 1.4-and 3.9-fold in p18 À / À and p18 À / À ; Brca1 þ /-glands, respectively (Supplementary Figure S1) . These results suggest that p18 may not be the only cell cycle inhibitor that interacts with Brca1 in vivo. Consistent with our previous finding in other tissues, 34 these data also indicate that other cell cycle inhibitors, for example, p21 and p16, compensate for the loss of p18 in mammary glands.
To provide further molecular evidence supporting the rescue of growth inhibition in Brca1 þ / À mammary by p18 loss, we directly examined Rb phosphorylation in both normal mammary tissues and tumors of different genotypes by using an antibody Brca1 controls luminal cell fate and basal-like tumor F Bai et al specifically recognizing Rb proteins phosphorylated at Ser608 by CDK4 and CDK6, 35, 36 the functional targets of p18. A visible and consistent increase of pRb-Ser608 phosphorylation, in both intensity and the number of positive cells, was detected in normal p18
À / À mammary epithelia at 1 year of age (8.9% in wild type to 25.4% in p18 À / À , Figure 1i ), confirming the activation of CDK4 and/or CDK6. Most pRb-Ser608-positive cells are luminal cells (Figure 1i and data not shown), consistent with the finding that p18 deficiency increased luminal progenitor cell proliferation and leads to luminal tumor development. 22 In all, 3.3% pRb-Ser608-positive luminal cells were detected in Brca1 þ / À females; however, both p18 À / À ;Brca1 þ / À and p18 À / À mice had a similar and notably higher percentage of positive luminal epithelial cells (22.9% Figure 1i ), supporting p18 as a downstream target of Brca1 in controlling luminal cell proliferation. This result also provides an explanation-that reduced RB pathway activity allows Brca1-mutated cells to continue to proliferate-for the development of a higher incidence of mammary tumors in p18 14, 37 or conditional mammary gland Brca1
À / À mice (20-25%). 15 p18;Brca1 germline double-mutant mice, unlike conditional Brca1 mutant mice in which Brca1 deficiency is directed to a certain cell lineage or developmental stage, offer a unique mouse model to study not only the function of Brca1 in mammary gland and tumor development but also the targeting preference and selectivity for mammary cell lineage and tumor cell type caused by germline mutation of Brca1.
Heterozygous germline mutation of Brca1 blocks the expansion of luminal progenitor cells and impairs luminal gene expression in p18 null mice To determine the effect of germline mutation of Brca1 on mammary cell fate determination, we dissected mammary glands À / À mice compared with wild-type littermates (6 weeks, 45.4 ± 6.1 versus 29 ± 3%; 9 months, 51.7 ± 3.1 versus 40.3 ± 5.1%) as we previously reported. 22 Notably, heterozygous germline mutation of Brca1 decreased the expansion of luminal progenitors in p18 À / À mice, reducing the CD29 lo CD24 þ population from 45.4 ± 6.1% in p18 À / À mice to 36.7±5% in p18 À / À ;Brca1 mice at 6 weeks, or from 51.7±3.1 to 39.3±4.2% at 9 months of age (Figures 2a and b) . When the SCA1 lo CD24
high population, also enriched with luminal progenitors, 40 was examined, similar results were detected, which was an increase from 46% in wild-type mice to 55% in p18 À / À mice, and a reduction down to 43% in the p18 À / À ;Brca1 mice ( Figure 2b ). Interestingly, the CD24 À CD10 þ population enriched for basal/ myoepithelial cells was increased in p18 À / À ;Brca1 þ / À mammary glands (2.1%) compared with either wild type (1.5%) or p18 To gain insight into the molecular mechanism underlying the function of Brca1 in maintaining luminal cell fate, we determined the expression of genes associated with luminal epithelial differentiation including Foxa1, Stat5a, Cdh1 and Epcam. [41] [42] [43] [44] Loss of p18 increased mRNA levels of Foxa1 and CDH1 in pubertal virgin mammary glands (Figure 2e ). Heterozygous germline mutation of Brca1, while having inhibitory function on the expression of most genes associated with luminal epithelial differentiation in pubertal glands with wild-type p18 þ / þ , significantly decreased their expression in p18 À / À glands (Figure 2e ). Taken together, these results suggest a function of Brca1 in maintaining proper luminal cell fate by preventing abnormally expanded luminal progenitor cells from aberrant differentiation and suppressing basal/myoepithelial cell differentiation.
Heterozygous germline mutation of Brca1 promotes the progression and malignant transformation of luminal tumors Less than 10% of Brca1 þ / À mice 14, 37 and about 20% of mice with both Brca1 alleles conditionally deleted 15 developed mammary tumors, suggesting that mutation of Brca1 alone is an insufficient factor to promote mammary tumorigenesis and that it may instead collaborate with mutation of other cancer genes. Taking advantage of the high rate of mammary tumor development in p18 mutant mice and the rescue of Brca1 þ / À -induced proliferation defects by p18 loss, we determined how germline mutation of Brca1 affects mammary tumorigenesis in p18-null background. We generated and analyzed a cohort of 51 p18;Brca1 double mutants. p18 À / À ; Brca1 þ / À mice had a similar penetrance of breast cancer (6/16 or 38% before 1 year, 13/15 or 87% by 22 months of age) as p18 À / À single-mutant mice (4/16 or 25% before one year, 19/23 or 83% by 22 months of age) (Table 1 ). Similarly, mammary tumor incidence in p18 þ / À ;Brca1 þ / À double heterozygous mutant mice was also comparable with that in p18 þ / À heterozygous mice (Table 1) . Importantly, the tumors showed marked morphological and histopathological differences (Figure 3 and below) . Mammary tumors developed in p18
þ / À double-mutant mice were more aggressive (increased necrosis, squamous metaplasia, spindle cells, nuclear-cytoplasm ratio, mitotic indices and metastasis) and contained heterogeneous cell types (Table 1) . Only 1 out of 19 (5.3%) mammary tumors from p18 -/-mice metastasized to the lung after 1 year of age, whereas 3 out of 10 (30%) p18 þ / À ;Brca1 þ / À and 4 out of 13 (31%) p18 À / À ;Brca1 þ / À mammary tumors metastasized to the lung and blood vessels at a similar age (Table 1 ). In accordance with the previous finding that Brca1 þ / À mice developed mammary tumors during late age at a very low penetrance, 14, 37 only 1 Brca1 þ / À mouse in a cohort of 11 (9%) developed mammary tumor at 25 months of age, similar to that observed in wild-type mice (1 in a cohort of 10, 10%) ( Table 1 ). The mammary tumor developed in the Brca1 þ / À single-mutant mouse appeared to be pathologically different (most cells were ER negative and about 2% of cells were positively stained with CK5) from that developed in the wild-type mouse (about 5% cells were ER positive and nearly no CK5-positive cells were detected), but the low incidence prevented us from firmly determining the 
Tumor
Wild type p18 Brca1 controls luminal cell fate and basal-like tumor F Bai et al significance of this finding. Together, these results suggest that p18 loss is an early and initiatory factor in breast cancer development, and that Brca1, although not efficient in suppressing mammary tumor initiation, has a critical role in preventing their progression, invasion and metastasis.
Heterozygous germline mutation of Brca1 converts estrogen receptor alpha (ERa)-positive luminal type tumors into ERanegative basal-like tumors in p18-deficient background In addition to morphological, pathological and cellular differences, the mammary tumors developed in the p18;Brca1 double-mutant (Figure 4a ). These results demonstrate that ERapositive-to-ERa-negative transformation proceeds, yet is not dependent on, malignant transformation and is likely a direct result of Brca1 reduction. p18 À / À mammary tumors were stained strongly and uniformly for CK8, and only 3 out of 19 (15.8%) tumors were detected CK5 positive in less than 5% tumor cells, suggesting that they predominantly consist of luminal epithelial cells (Figures 4c and  d and Table 1 ). Notably, p18 À / À ;Brca1 þ / À mammary tumors were highly heterogeneous: although the majority of cells (60 -80%) in most tumors were positive for CK8, a significant portion of highly disorganized clustering cells (20-40%) stained positive by CK5 (in scattering, mixing or chimeric patterns) (Figures 4c and d Figure S1 ). Three double-mutant mammary tumors, one from p18 À / À ;Brca1 þ / À and the other two from p18 þ / À ;Brca1 þ / À mice, displayed multiple tumor cell types and were identified as 495% CK5 þ tumors (Figure 4d ). Separate immunohistochemical staining and microscopic examination of more and larger sections confirmed CK5 positivity in p18 Immunostaining of p18 À / À ;Brca1 þ / À mammary tumors with antibodies specific to Brca1 and CK5 in serial sections revealed a mutually exclusive staining pattern between these two proteins in the tumor cells (Figure 4f) , suggesting a function of Brca1 in suppressing the expression of basal-like features. This notion is consistent with a previous finding that the function of Brca1 is important in maintaining luminal cell features. The remaining wild-type Brca1 allele was retained in all 14 p18;Brca1 doublemutant tumors (nine from p18 À / À ;Brca1 þ / À mice and five from p18 þ / À ;Brca1 þ / À mice) when genomic DNA was prepared from blended tumor cells (data not shown), but was lost in at least 4 out of 10 tumors when genomic DNA was prepared from CK5 þ cells isolated by immunofluorescent-staining-guided laser capture microdissection under microscopy (Figure 4g) , confirming an important role of Brca1 in suppressing CK5 þ basal-like tumor development.
Together, these five features of the p18 À / À ;Brca1 þ / À mammary tumors-high degree of heterogeneity, increased population of CK5-positive cells, loss of wild-type allele of Brca1 in CK5-positive tumor cells, ERa negativity and invasiveness and metastasis-are consistent with an interpretation that haploid loss of Brca1, although not efficiently inducing a high incidence of mammary tumor by itself, significantly changed the properties of mammary tumors induced by p18 loss, resulting in their malignant and luminal-to-basal-like transformation.
DISCUSSION
In this paper, we reported that Brca1 was predominantly expressed in mammary luminal epithelial cells and that Brca1 negatively regulated p18, whose loss led to the expansion of luminal progenitor cells. Heterozygous germline mutation of Brca1 blocked the expansion of luminal progenitor cells and inhibited luminal gene expression in p18-null mice, suggesting a function of Brca1 in maintaining proper luminal cell lineage by preventing abnormally expanded luminal progenitor cells from aberrant differentiation and suppressing basal/myoepithelial cell differentiation. These data also answered the question as to why conditional deletion of Brca1 in mammary luminal, but not in basal cell lineage, impaired mammary development. 45, 46 To the best of our knowledge, this is the first genetic evidence directly showing that Brca1 maintains luminal cell fate in normal mammary development.
BRCA1 has long been suggested to have an important role in mammary epithelial cell differentiation, 10, [47] [48] [49] [50] which was concluded, however, mostly from either association of BRCA1 expression pattern with mammary cell maturation and differentiation or cell culture system. Knockdown of BRCA1 in human mammosphere-initiating cells blocked differentiation of luminal progenitor cells in vitro and in mouse xenografts. 7 Somatic deletion of Brca1 in basal cells by K14-and K6a-cre did not cause any observable changes in the normal mammary gland, 45 whereas Figure 3 . Brca1 heterozygosity induces metastatic conversion of p18-deficient mammary tumors. Representative hematoxylin and eosin staining of mammary tumors derived from p18 À / À ;Brca1 þ / À mice are shown (b-j). p18 À / À mammary tumor (a) is shown as a control. Note the tubular carcinoma (a) in p18 À / À mice that retained a relatively well-differentiated gland structure; papillary carcinoma in p18 þ / À ; Brca1 þ / À mice that have finger-like stalks with a central fibrovascular core covered with epithelium (b); poorly differentiated carcinoma with squamous metaplasia that is the major tumor type developed in p18 À / À ;Brca1 þ / À mammary and contains highly pleomorphic tumor cells with numerous mitoses shown in the inset (c); poorly differentiated, infiltrating p18 À / À ;Brca1 þ / À breast cancer with few tubules, highly pleomorphic nuclei and many mitoses surrounded by connective tissues (d); cysts frequently observed in the p18 À / À ;Brca1 þ / À papillary carcinoma that contained abundant fluid and irregular epithelial islands with cribriform pattern and poorly differentiated and high nuclear/ cytoplasmic ratio shown in the inset (e); and mammary carcinoma metastasized to the lung (T) found in a p18 À / À ;Brca1 þ / À mouse (f ). A mammary tumor (g) developed in p18 À / À ;Brca1 þ / À mice metastasized to lung (h) that was stained with antibodies against CK5 (green) and CK8 (red) and shown in inset (h). Note the similar tumor cell type in lung (h) with the original tumor in mammary (g). A mammary tumor from p18 À / À ;Brca1 þ / À mice displayed multiple tumor cell types (i, lower power, j, higher power), which was subsequently identified as 495% CK5 þ basal-like tumor. 46 implying that the mutation of Brca1 preferentially targets luminal cell lineage. Recently, two groups identified luminal progenitors as the target cells for basal-like tumor development in BRCA1 germline mutation carriers. 8, 9 However, because of the unknown genetic background of the patients in addition to BRCA1 mutation and the limitation of the tissue sample collection, discrepancy in the results-one showing the expanded 8 and the other showing the decreased 9 luminal progenitors-was observed in disease-free breast tissues of BRCA1 mutation carriers. Our results suggest that germline mutations in Brca1 impair luminal cell lineage and mammary development and, when combined with reduced function of the RB pathway, for example, loss of p18, promote basal-like trans-differentiation.
The molecular mechanism underlying the function of Brca1 in maintaining luminal cell fate in normal mammary development and breast cancer formation is largely elusive. Brca1 is a multifunctional protein with roles in DNA-damage repair, cell cycle control, transcriptional regulation and ubiquitination. It is the ability of BRCA1 to regulate transcription that controls normal differentiation and suppresses tumor development. 51, 52 Brca1 regulates transcription at several levels, from interacting with sequence-specific transcriptional factors, such as p53, Myc, STAT1, CtIP and Oct1, to interactions with the RNA polymerase II complex and enzymes involved in chromatin remodeling, such as HDAC1 and HDAC2, SWI/SNF complex and p300/CBP. [53] [54] [55] [56] Many genes were found to be regulated by Brca1, including those associated with luminal differentiation, such as Foxa1 and ERa. [55] [56] [57] [58] We show in this study that heterozygous germline mutation of Brca1 leads to the downregulation of luminal differentiation genes including Foxa1, Stat5a, Cdh1 and Epcam in tumor-free mammary glands, which not only confirms previous findings, most of which were derived from cell culture systems, but also provides the genetic evidence supporting the role of Brca1 in regulation of these genes in cell fate determination and maintenance of normal mammary stem and progenitor cells. Consistent with this finding, we also report that Brca1 deficiency converts ER-positive luminal tumors into ER-negative basal-like tumors, suggesting that Brca1 also functions to regulate luminal differentiation genes and maintain luminal tumor cell fate in breast cancer progression.
In accordance with observations derived from Brca1 mutant mice in combination with mutations in the p53 pathway, 29, 59 we found that Brca1 mutation induced growth inhibition in mice and rarely led to tumor formation, but converted p18-deficient luminal tumors into invasive basal-like tumors, indicating that Brca1 mutation has an important role in tumor progression, rather than in initiation of breast cancer. Human basal-like breast tumors that develop in Brca1 mutation carriers are heterogeneous, 60 and some have been found to be mixed epithelial/mesenchymal metaplastic carcinomas with mesenchymal features. 61 We observed that p18 À / À ;Brca1 þ / À mammary tumors, unlike p18 À / À tumors, are highly heterogeneous, with some exhibiting various degrees of whorls and clusters of spindle-shaped tumor cells (Figures 3i  and j) , a typical mesenchymal characteristic. These observations imply that germline mutation of Brca1 may lead to epithelial-tomesenchymal transition (EMT), which has an important role in intratumoral heterogeneity and breast basal-like tumor progression. 62 It has recently been reported that Slug, an EMT-associated transcription factor, is aberrantly expressed in the breast of Brca1 mutant carriers, and that it is necessary for the increase in the basal-like phenotypes of human breast cancers created in mouse by transformation of BRCA1 mut/ þ patient-derived breast epithelial cells with four tumorigenic genes (TP53 R175H , CCND1, PI3KCA and KRAS G12V ). 9 Brca1 was also found to repress FoxC1, FoxC2 and Twist, 63, 64 all of which are typical EMT-associated transcription factors, suggesting that Brca1 may function in controlling EMT. Whether Brca1 mutation induces EMT and how it contributes to basal-like tumor development and progression remains to be investigated.
Most, if not all, genetic studies used co-mutation of one of the genes in the p53 pathway to overcome the growth defects induced by the mutation of Brca1 in mice. 13, 29, 30, 59 Gene expression analysis segregated mammary tumors derived from
mice into basal-like type tumor. 65, 66 It is, however, unclear in these studies whether germline mutation of Brca1 alone contributed to basal-like tumor development because mammary tumors formed in p53 þ / À mice fall into multiple molecular subtypes including the basal-like subtype. 67 Conditional deletion of Brca1 in mammary luminal cell lineage by MMTV-Cre or Wap-Cre resulted in basal-like tumor development in p53 À / À or p53 þ / À mice, 59 suggesting that the cells of origin of basal-like tumors could be luminal cells. Indeed, conditionally directing Brca1 deficiency to p53 þ / À luminal progenitor cells by Blg-Cre led to basal-like tumor development, which was similar to human Brca1 breast cancers, supporting the notion that Brca1 mutant basal-like mammary tumors could originate from luminal progenitors. 64 In sum, this study demonstrates that germline mutation of Brca1 is not efficient in initiating mammary tumor formation and that loss of p18 results in the expansion of luminal progenitors, which is an early and initiatory factor in luminal tumor development. Germline mutation of Brca1 alters luminal tumor cell differentiation and activates basal-like features, converting ERpositive luminal tumors into ER-negative basal-like tumors. These results suggest a novel mechanism-causing luminal-to-basal transformation-for the development of basal-like breast cancer in familial BRCA1 carriers and establish a unique mouse model to develop the therapeutic strategies to target both luminal and basal-like breast cancers.
MATERIALS AND METHODS Mice
The generation and genotyping of p18 and Brca1 mutant mice have been described previously; 68, 69 p18 and Brca1 mutant mice have been backcrossed for 7 and 410 generations with BALB/c mice, respectively. Cohorts were housed and analyzed in a common setting, and agematched or littermate controls were used for all experiments as indicated. IACUC (Institutional Animal Care and Use Committee) at the University of North Carolina and University of Miami approved all procedures.
Histopathology and immunohistochemistry
Histopathology and immunohistochemistry were performed as described previously. 18 The following primary antibodies were used: to p-Rb-S608, (Cell Signaling, Danvers, MA, USA), CK5 (Covance, Princeton, NJ, USA), CK8 (American Research Products, Waltham, MA, USA), CK14, SMA (Thermo Scientific, Rockford, IL, USA), ERa, Brca1 (Santa Cruz, Santa Cruz, CA, USA) and Ki67 (Novocastra Laboratories, Newcastle upon Tyne, UK). Immunocomplexes were detected using the Vectastain ABC alkaline phosphatase kit (Vector Laboratories, Burlingame, CA, USA), or using FITC-and rhodamine-conjugated secondary antibodies (Jackson Immunoresearch, West Grove, PA, USA).
Immunofluorescent-staining-guided laser capture microdissection and LOH analysis Ten-micrometer sections were deparaffinized and lightly stained with antibody against CK5. Using a PixCell lle Laser Capture Microdissection system (Arcturus, Mountain View, CA, USA), the lesions that were positively stained with CK5 were isolated from the slides. Particular care was taken to avoid contamination by the surrounding tissue. DNA isolation and LOH analysis were performed as described. 18, 19 Mammary cell preparation, FACS analysis, cell sorting and colonyformation assay Mammary glands were dissected from female mice at the indicated age. After mechanical dissociation, the tissue was processed as previously described. 22, 38, 70 Brca1 controls luminal cell fate and basal-like tumor F Bai et al
